Allarity Therapeutics, Inc.

Allarity Therapeutics is a clinical-stage biotechnology company developing precision medicine approaches to oncology. The company focuses on anti-cancer therapeutics paired with companion diagnostics, addressing patients with limited treatment options. Its core technology platform, the drug response predictor, generates patient-specific diagnostic tools designed to identify which individuals are likely to benefit from particular drug candidates.

The company's lead program is Stenoparib, a dual PARP1/2 inhibitor currently in phase 2 clinical trials for advanced and recurrent ovarian cancer. Allarity is developing Stenoparib-DRP, a companion diagnostic product intended to identify patient populations most likely to respond to treatment. The companion diagnostic approach represents the primary business model, with revenue dependent on successful clinical development and eventual regulatory approval of the underlying therapeutic candidate.

Allarity operates as a lean organization with six full-time employees and maintains headquarters in Boston, Massachusetts. The company was incorporated in Delaware in 2004. At this stage of development, the organization generates minimal revenue, with financial performance dependent on milestone achievements in clinical trials and potential partnerships or financing activities. The company is listed on Nasdaq.